Literature DB >> 17713474

Physical and cognitive performance and burden of anticholinergics, sedatives, and ACE inhibitors in older women.

Y-J Cao1, D E Mager, E M Simonsick, S N Hilmer, S M Ling, B G Windham, V Crentsil, S Yasar, L P Fried, D R Abernethy.   

Abstract

Polypharmacy, common in older people, confers both risk of adverse outcomes and benefits. We assessed the relationship of commonly prescribed medications with anticholinergic and sedative effects to physical and cognitive performance in older individuals. The study population comprised 932 moderately to severely disabled community-resident women aged 65 years or older who were participants in the Women's Health and Aging Study I. A scale based on pharmacodynamic principles was developed and utilized as a measure of drug burden. This was related to measures of physical and cognitive function. After adjusting for demographics and comorbidities, anticholinergic drug burden was independently associated with greater difficulty in four physical function domains with adjusted odds ratios (95% confidence interval (CI)) of 4.9 (2.0-12.0) for balance difficulty; 3.2 (1.5-6.9) for mobility difficulty; 3.6 (1.6-8.0) for slow gait; 4.2 (2.0-8.7) for chair stands difficulty; 2.4 (1.1-5.3) for weak grip strength; 2.7 (1.3-5.4) for upper extremity limitations; 3.4 (1.7-6.9) for difficulty in activities of daily living; and 2.4 (95% CI, 1.1-5.1) for poor performance on the Mini-Mental State Examination. Sedative burden was associated only with impaired grip strength (3.3 (1.5-7.3)) and mobility difficulty (2.4 (1.1-5.3)). The burden of multiple drugs can be quantified by incorporating the recommended dose regimen and the actual dose and frequency of drug taken. Anticholinergic drug burden is strongly associated with limitations in physical and cognitive function. Sedative burden is associated with impaired functioning in more limited domains. The risk associated with exposure of vulnerable older women to drugs with anticholinergic properties, and to a lesser extent those with sedative properties, implies that such drugs should not be used in this patient group without compelling clinical indication.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17713474     DOI: 10.1038/sj.clpt.6100303

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  63 in total

1.  Comprehensive medication review: development of a collaborative procedure.

Authors:  Saija Leikola; Lea Tuomainen; Sirpa Peura; Antti Laurikainen; Alan Lyles; Eeva Savela; Marja Airaksinen
Journal:  Int J Clin Pharm       Date:  2012-06-19

2.  Associations between drug burden index and mortality in older people in residential aged care facilities.

Authors:  Nicholas M Wilson; Sarah N Hilmer; Lyn M March; Jian Sheng Chen; Danijela Gnjidic; Rebecca S Mason; Ian D Cameron; Philip N Sambrook
Journal:  Drugs Aging       Date:  2012-02-01       Impact factor: 3.923

3.  A preliminary study of anticholinergic burden and relationship to a quality of life indicator, engagement in activities, in nursing home residents with dementia.

Authors:  Ann Kolanowski; Donna M Fick; Judy Campbell; Mark Litaker; Malaz Boustani
Journal:  J Am Med Dir Assoc       Date:  2009-01-09       Impact factor: 4.669

4.  Impact of residential medication management reviews on drug burden index in aged-care homes: a retrospective analysis.

Authors:  Prasad S Nishtala; Sarah N Hilmer; Andrew J McLachlan; Paul J Hannan; Timothy F Chen
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

5.  Innovative collaborative practice to optimize pharmacotherapy for frail older patients.

Authors:  Shanna Trenaman; Susan K Bowles; Laurie Mallery; Katalin Koller; Melissa Andrew
Journal:  Can J Hosp Pharm       Date:  2014-09

6.  Association between anticholinergic (atropinic) drug exposure and cognitive function in longitudinal studies among individuals over 50 years old: a systematic review.

Authors:  Laurine Andre; Adeline Gallini; François Montastruc; Jean-Louis Montastruc; Antoine Piau; Maryse Lapeyre-Mestre; Virginie Gardette
Journal:  Eur J Clin Pharmacol       Date:  2019-08-29       Impact factor: 2.953

Review 7.  A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs.

Authors:  Cara Tannenbaum; Amélie Paquette; Sarah Hilmer; Jayna Holroyd-Leduc; Ryan Carnahan
Journal:  Drugs Aging       Date:  2012-08-01       Impact factor: 3.923

8.  Geriatric syndromes and incident disability in older women: results from the women's health initiative observational study.

Authors:  Andrea L Rosso; Charles B Eaton; Robert Wallace; Rachel Gold; Marcia L Stefanick; Judith K Ockene; J David Curb; Yvonne L Michael
Journal:  J Am Geriatr Soc       Date:  2013-03-01       Impact factor: 5.562

9.  Drug burden index score and functional decline in older people.

Authors:  Sarah N Hilmer; Donald E Mager; Eleanor M Simonsick; Shari M Ling; B Gwen Windham; Tamara B Harris; Ronald I Shorr; Douglas C Bauer; Darrell R Abernethy
Journal:  Am J Med       Date:  2009-12       Impact factor: 4.965

Review 10.  Effect of Angiotensin-Converting Enzyme Inhibitors on Physical Function in Elderly Subjects: A Systematic Review and Meta-Analysis.

Authors:  Ling-shan Zhou; Ling-jie Xu; Xue-qing Wang; Yi-huan Huang; Qian Xiao
Journal:  Drugs Aging       Date:  2015-09       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.